Misplaced Pages

Maridebart cafraglutide

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Redirected from AMG 133) Experimental medication Pharmaceutical compound
Maridebart cafraglutide
Clinical data
Other namesAMG 133
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Maridebart cafraglutide (also known as MariTide; developmental name AMG 133) is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor (GLP-1R) and an antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). Namely, MariTide consists of a monoclonal antibody against GIPR conjugated to two peptidic GLP-1R agonist molecules via amino acid linkers. In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested.

References

  1. Beasley, Deena (2024-02-06). "Amgen taking different path to weight loss windfall". Reuters. Retrieved 2024-03-06.
  2. Véniant, Murielle M.; Lu, Shu-Chen; Atangan, Larissa; Komorowski, Renee; Stanislaus, Shanaka; Cheng, Yuan; Wu, Bin; Falsey, James R.; Hager, Todd; Thomas, Veena A.; Ambhaikar, Malhar; Sharpsten, Lucie; Zhu, Yineng; Kurra, Vamsi; Jeswani, Rohini (2024-02-05). "A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings". Nature Metabolism. 6 (2): 290–303. doi:10.1038/s42255-023-00966-w. ISSN 2522-5812. PMC 10896721. PMID 38316982.
  3. Hammoud, Rola; Drucker, Daniel J. (April 2023). "Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1". Nature Reviews Endocrinology. 19 (4): 201–216. doi:10.1038/s41574-022-00783-3. ISSN 1759-5037.
  4. Jepsen, Mathies M.; Christensen, Mikkel B. (3 July 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240.
  5. Bailey, Clifford J.; Flatt, Peter R.; Conlon, J. Michael (1 March 2023). "An update on peptide-based therapies for type 2 diabetes and obesity". Peptides. 161: 170939. doi:10.1016/j.peptides.2023.170939. ISSN 0196-9781.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Maridebart cafraglutide Add topic